Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Lung Cancer

    FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

    On January 26, 2023, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda®) for adjuvant treatment following resection and platinum-based chemotherapy of patients with stage IB (T2a ≥ 4 cm), II, or IIIA non-small cell lung cancer.

     

    January 30, 2023
    FDA Grants Accelerated Approval to Adagrasib for KRAS G12C–Variant Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Adagrasib for KRAS G12C–Variant Non-Small Cell Lung Cancer

    On December 12, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib (Krazati®), a RAS GTPase family inhibitor, for adult patients with KRAS G12C–variant locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, and who have received at least one prior systemic therapy.

    December 14, 2022
    FDA Approves Tremelimumab in Combination With Durvalumab and Platinum-Based Chemotherapy for Metastatic Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Tremelimumab in Combination With Durvalumab and Platinum-Based Chemotherapy for Metastatic Non-Small Cell Lung Cancer

    On November 10, 2022, the U.S. Food and Drug Administration approved tremelimumab (Imjudo®) in combination with durvalumab (Imfinzi®) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer with no sensitizing epidermal growth factor receptor (EGFR) variant or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

    November 11, 2022
    Most Lung Cancer Genetic Variants Are Clinically Actionable and All Patients Should Get Biomarker Testing
    Cancer research

    Most Lung Cancer Genetic Variants Are Clinically Actionable and All Patients Should Get Biomarker Testing

    More than 95% of germline genetic variants identified through genetic testing in patients with lung cancer are potentially clinically actionable, researchers reported in study findings during the 2022 ASCO Plenary Series Program, leading them to recommend testing all patients with the disease.

    November 02, 2022
    FDA Approves Selpercatinib for RET Fusion-Positive Non-Small Cell Lung Cancer and Locally Advanced or Metastatic Solid Tumors
    U.S. Food and Drug Administration (FDA)

    FDA Approves Selpercatinib for RET Fusion-Positive Non-Small Cell Lung Cancer and Locally Advanced or Metastatic Solid Tumors

    On September 21, 2022, the U.S. Food and Drug Administration (FDA) granted regular approval to selpercatinib (Retevmo®) for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion and accelerated approval for adults with locally advanced or metastatic solid tumors with a RET gene fusion that progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

    September 23, 2022
    FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki for HER2-Variant Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki for HER2-Variant Non-Small Cell Lung Cancer

    On August 11, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu®) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 (HER2) variants, as detected by an FDA-approved test, and who have received a prior systemic therapy. This is the first drug approved for HER2-variant NSCLC.

    August 15, 2022
    FDA Approves Capmatinib for Metastatic Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Capmatinib for Metastatic Non-Small Cell Lung Cancer

    On August 10, 2022, the U.S. Food and Drug Administration (FDA) granted regular approval to capmatinib (Tabrecta®) for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation leading to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test.

    August 15, 2022
    E-Cigarettes Increase Risk of Lung and Bladder Cancer More Than Traditional Cigarettes
    Cancer research

    E-Cigarettes Increase Risk of Lung and Bladder Cancer More Than Traditional Cigarettes

    People with a history of e-cigarette use have a higher risk of developing both lung and bladder cancer than never smokers or even users of regular cigarettes, according to study findings researchers reported during the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium.

    May 18, 2022
    CMS Expands Eligibility Criteria for Lung Cancer Screening With Low-Dose Computed Tomography
    Lung Cancer

    CMS Expands Eligibility Criteria for Lung Cancer Screening With Low-Dose Computed Tomography

    More Medicare beneficiaries now meet age, smoking history, and other criteria for lung cancer screening and are now eligible to receive low-dose computed tomography (LDCT), according to a February 2022 memo from the Centers for Medicare and Medicaid Services (CMS).

    April 06, 2022
    FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage Non-Small Cell Lung Cancer

    On March 4, 2022, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting, representing the first FDA approval for neoadjuvant therapy for early-stage NSCLC.

    March 18, 2022
    How Liquid Biopsies Are Used in Cancer Treatment Selection
    Cancer treatments

    How Liquid Biopsies Are Used in Cancer Treatment Selection

    Biomarker testing is an essential tool when choosing the right treatment for many advanced solid cancers. However, tissue-based testing may take weeks to get results with a chance that not enough tissue was collected to complete the entire biomarker panel. Blood draw–based liquid biopsies may be a useful alternative to identify a tumor’s biomarker details and can be performed by testing for circulating tumor DNA (ctDNA).

    February 03, 2022
    Never Smokers With Lung Cancer May Have One of Three Molecular Subtypes
    Lung Cancer

    Never Smokers With Lung Cancer May Have One of Three Molecular Subtypes

    Most lung cancers in patients who have no smoking history are the result of natural genetic variants in the body that can be classified into one of three molecular subtypes, researchers reported in study finding published in Nature Genetics.

    January 26, 2022
    Oncology Drug Reference Sheet: Amivantamab-Vmjw
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Amivantamab-Vmjw

    After clinical trials demonstrated a 40% overall response rate with 63% of responses lasting six months or more, on May 21, 2021, the U.S. Food and Drug Administration (FDA) approved amivantamab-vmjw (RybrevantTM) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion variants, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

    December 28, 2021
    First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer
    Cancer research

    First KRAS-Targeted Therapy Receives FDA Approval for Lung Cancer

    Sotorasib offers a durable clinical benefit without new safety signals in patients with previously treated KRAS p.G12C-variant non-small cell lung cancer, according to the results of a clinical trial that led to the therapy’s U.S. Food and Drug Administration (FDA) approval. The researchers reported the findings in the New England Journal of Medicine.

    November 24, 2021
    Oncology Drug Reference Sheet: Sotorasib
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Sotorasib

    After clinical trials demonstrated an overall response rate of 36% and median response duration of 10 months, the U.S. Food and Drug Administration granted sotorasib (LumakrasTM) accelerated approval on May 28, 2021, for the treatment of adults with KRAS G12C–altered locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

    November 23, 2021
    FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

    On October 15, 2021, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II–IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression on ≥ 1% of tumor cells as determined by an FDA-approved test. 

    October 15, 2021
    Study Shows Anti-Vaping Advertising Campaigns Are Effective in Educating Youth About Tobacco Dangers
    Cancer health policy

    Study Shows Anti-Vaping Advertising Campaigns Are Effective in Educating Youth About Tobacco Dangers

    Young people who see anti-vaping advertisements and prevention campaigns are more likely to have accurate e-cigarette knowledge, which can lead to a decrease in tobacco use and consequently, lung cancer diagnoses, according to a July 2021 study from the Truth Initiative, an organization devoted to educating youth about smoking and tobacco industries.

    September 02, 2021
    Overall Youth Tobacco Use Declines, but E-Cigarette Use Climbs, According to National Survey Results
    Lung Cancer

    Overall Youth Tobacco Use Declines, but E-Cigarette Use Climbs, According to National Survey Results

    American youth reported a decline in using any tobacco product in 2020 compared to 2019 but no significant decrease in the use of cigarettes, hookah, pipe tobacco, or heated tobacco products, according to 2020 U.S. Food and Drug Administration (FDA) survey findings on youth tobacco use. Despite the decline, FDA said that the data shows “disturbingly high rates of frequent and daily e-cigarette use” and strong nicotine dependence among youth.

    August 16, 2021
    Lung, Melanoma, and Overall Cancer Death Rates Decline, According to 2021 Report
    Lung Cancer

    Lung, Melanoma, and Overall Cancer Death Rates Decline, According to 2021 Report

    Cancer mortality for all racial and ethnic groups in the United States continues to decline, with death rates for lung cancer and melanoma decreasing faster than others, according to findings that the American Cancer Society (ACS), the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries (NAACCR) published in their July 2021 Annual Report to the Nation on the status of cancer.

    August 02, 2021
    On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib (Lumakras™), a RAS GTPase family inhibitor, for adult patients with KRAS G12Cmutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-Mutated NSCLC

    On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib (Lumakras™), a RAS GTPase family inhibitor, for adult patients with KRAS G12Cmutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.

    June 01, 2021
    FDA Grants Accelerated Approval to Amivantamab-Vmjw for Metastatic NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Amivantamab-Vmjw for Metastatic NSCLC

    On May 21, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab-vmjw (Rybrevant™), a bispecific antibody directed against epidermal growth factor receptor (EGFR) and MET receptor, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. FDA also approved the Guardant360® CDx as a companion diagnostic.

    May 24, 2021
    Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer
    Lung Cancer

    Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer

    Testing for molecular biomarkers has become a mainstay in determining treatment approaches for advanced-stage non-small cell lung cancer. Typically, next-generation sequencing identifies any potential genomic variants that are associated with oncogenic driver events and can be targeted with oral tyrosine kinase inhibitors.

    May 17, 2021
    Muscle Quality Predicts Efficacy of NSCLC Immunotherapy
    Research

    Muscle Quality Predicts Efficacy of NSCLC Immunotherapy

    Patients with higher muscle quality during treatment with PD-1/PD-L1 inhibitor monotherapy for non-small cell lung cancer (NSCLC) had higher overall response rates and longer progression-free survival than patients with lower-quality skeletal muscle, researchers reported in study findings published in Cancer Medicine.

    March 31, 2021
    Lung Cancer Screening Guidelines to Reduce Disparities May Increase Them Instead—But Risk Model Can Help
    Cancer screening

    Lung Cancer Screening Guidelines to Reduce Disparities May Increase Them Instead—But Risk Model Can Help

    The draft 2020 U.S. Preventive Services Task Force (USPSTF) lung cancer screening recommendations were intended to increase the number of high-risk minorities eligible for lifesaving tests. And they do, but not as much as USPSTF anticipated, still leaving gaps and disparities, researchers reported in the Journal of the National Cancer Institute. They created a risk model to augment the guidelines that eliminated the disparities for most racial groups.

    March 10, 2021
    FDA Approves Lorlatinib for ALK-Positive Metastatic NSCLC
    Lung Cancer

    FDA Approves Lorlatinib for ALK-Positive Metastatic NSCLC

    On March 3, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to lorlatinib (Lorbrena®) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. FDA also approved the Ventana ALK (D5F3) CDx Assay as a companion diagnostic for lorlatinib.

    March 04, 2021
    FDA Approves Cemiplimab-Rwlc for NSCLC With High PD-L1 Expression
    Clinical practice

    FDA Approves Cemiplimab-Rwlc for NSCLC With High PD-L1 Expression

    On February 22, 2021, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation and whose tumors have high PD-L1 expression (tumor proportion score ≥ 50%) as determined by an FDA-approved test, with no estimated aberrations to glomerular filtration rate, anaplastic lymphoma kinase, or receptor tyrosine kinase (encoded by the ROS1 gene). 

    February 23, 2021
    FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC

    On February 3, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tepotinib (Tepmetko®) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition exon 14 skipping alterations.

    February 03, 2021
    First-Time Smoking Age Increases Among Young Adults
    Lung Cancer

    First-Time Smoking Age Increases Among Young Adults

    Although overall smoking rates are decreasing among adolescents and young adults, a new trend is emerging: those who smoked their first cigarette between ages 18–23 increased from 21% in 2002 to 43% in 2018, researchers reported in JAMA Network Open. The increase in young adult first-time smokers comes at a time when smoking initiation rates are decreasing among younger teenagers.

    January 27, 2021
    U.S. Senate Designates November as National Lung Cancer Awareness Month
    Lung Cancer

    U.S. Senate Designates November as National Lung Cancer Awareness Month

    The U.S. Senate unanimously passed a resolution designating November as National Lung Cancer Awareness Month and supporting early detection of lung cancer, a crucial awareness with smoking on the rise among young adults.

    January 07, 2021
    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations
    U.S. Food and Drug Administration (FDA)

    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso®) as adjuvant therapy after tumor resection for patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. 

    December 21, 2020
    ONS Supports Bipartisan  Resolution  to Recognize November as National Lung Cancer Awareness Month
    Lung Cancer

    ONS Supports Bipartisan  Resolution  to Recognize November as National Lung Cancer Awareness Month

    Lung cancer knows no state boundary or political ideology. But it can bring the two sides together, like it did when U.S. Senators Tina Smith (D-MN), member of the Senate Health Committee, and Marco Rubio (R-FL) introduced a resolution to recognize November as National Lung Cancer Awareness Month. The resolution, which ONS supports, promotes the importance of and need to improve lung cancer early detection.

    December 14, 2020
    Smoking Initiation Declines in Teens, Rises in Young Adults
    Lung Cancer

    Smoking Initiation Declines in Teens, Rises in Young Adults

    The average age at which cigarette users start to smoke regularly has risen. Although the figures dropped from 45% of adults smoking cigarettes in the 1960s to 14% today, and teen smoking declined to 2.4% by 2019, results of a recent study show an upward trend of underage tobacco use in young adults.  

    December 01, 2020
    Oncology Drug Reference Sheet: Selpercatinib
    Clinical practice

    Oncology Drug Reference Sheet: Selpercatinib

    In May 2020, the U.S. Food and Drug Administration gave accelerated approval for selpercatinib (Retevmo®) to treat RET-altered non-small cell lung cancer or thyroid cancer based on overall response rate and duration of response. Selpercatinib fights cancer by impeding RET protein activity. The determining clinical trial results demonstrated that it reduced tumor size in more than 50% of patients and was associated with fewer adverse reactions than other drugs that block the RET protein.

    November 24, 2020
    Resource Helps Explain the Potential Dangers of E-Cigarettes to Providers and Patients
    Lung Cancer

    Resource Helps Explain the Potential Dangers of E-Cigarettes to Providers and Patients

    E-cigarettes are dangerous and their risks outweigh any potential smoking-cessation benefits, the U.S. Government Accountability Office explained in a new two-page resource that analyzes the science and technology behind the devices.

    November 06, 2020
    Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship
    Lung Cancer

    Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship

    Lung cancer is the leading cause of cancer death in the United States, accounting for about one quarter of cancer deaths, and more than a quarter of million lung cancer diagnoses are projected in the United States for 2020. Lung cancer has various types, pathologies, and histologies, each with its own prognosis and treatment plan. Non-small cell lung cancer consists of about 80%–85% of lung cancer diagnoses.

    November 05, 2020
    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions

    On September 4, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pralsetinib (Gavreto™) for adult patients with metastatic, RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

    September 10, 2020
    Treating Mental Health May Improve Lung Cancer Survival
    Cancer research

    Treating Mental Health May Improve Lung Cancer Survival

    Patients with lung cancer who also had mental health disorders saw improved cancer-related outcomes when their mental illness was treated, according to findings from a study published in JAMA Oncology.

    September 02, 2020
    FDA Approves First Liquid Biopsy NGS Companion Diagnostic Test for NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Liquid Biopsy NGS Companion Diagnostic Test for NSCLC

    On August 7, 2020, the U.S. Food and Drug Administration (FDA) approved the Guardant360 CDx assay as the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in patients with metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies in one diagnostic test to guide treatment decisions. 

    August 11, 2020
    Manage Immune-Related Adverse Events in Patients on Durvalumab
    Adverse events

    Manage Immune-Related Adverse Events in Patients on Durvalumab

    Durvalumab immunotherapy became a new standard of care for patients with stage III unresectable non-small cell lung cancer whose disease did not progress following two cycles of platinum-based chemoradiotherapy after its approval in February 2018, and in March 2020, its indication was expanded for use as first-line treatment in patients with extensive-stage small cell lung cancer as well. Key to keeping patients on immunotherapy treatment and giving them the best chance at long-term survival is effective management of immune-related adverse events.

    August 11, 2020
    NIH Study Links Cigarette Smoking to Higher Stroke Risk in African Americans
    Lung Cancer

    NIH Study Links Cigarette Smoking to Higher Stroke Risk in African Americans

    The disproportionate adverse health impact from smoking on African Americans is striking. Although oncology nurses are well aware of tobacco’s carcinogenic effects, they also need to understand the implications for comorbid conditions they may see in smokers with cancer. A recent study, through the National Institutes of Health (NIH), confirmed that African Americans have a 2.5 times higher incident of smoking-related strokes than those who never smoke.

    July 06, 2020
    Nurses Obliged to End Racism; Tobacco Industry's Manipulative Marketing
    Cancer healthcare advocacy

    Nurses Obliged to End Racism; Tobacco Industry's Manipulative Marketing

    Along with many other healthcare organizations, including ONS, last week the American Nurses Association (ANA) took a bold stand against racism, calling it a public health crisis. On June 12, 2020, ANA President Earnest Grant shared how racism is embedded in health care and what nurses should do to end it.

    June 22, 2020
    FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression

    On May 18, 2020, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) for first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 staining ≥ 50% of tumor cells [TC] or PD-L1-stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area), with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations. 

    May 19, 2020
    FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic Non-Small Cell Lung Cancer

    On May 15, 2020, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥ 1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. 

    May 18, 2020
    FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions

    On May 8, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo™) for adult patients with metastatic, RET fusion–positive non-small cell lung cancer (NSCLC); adult and pediatric patients aged 12 or older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and adult and pediatric patients aged 12 or older with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are refractory to radioactive iodine (if radioactive iodine is appropriate). This is the first drug approval for RET genetic alterations.

    May 12, 2020
    FDA Grants Accelerated Approval to Capmatinib for Metastatic Non-Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Capmatinib for Metastatic Non-Small Cell Lung Cancer

    On May 6, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib (Tabrecta™) for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to mesenchymal-epithelial transition exon 14 skipping, as detected by an FDA-approved test. It is the first drug approval for this specific patient population and the first targeted therapy for the indication.

    May 07, 2020
    House Tells FDA to Ban E-Cigarettes During COVID-19
    COVID-19

    House Tells FDA to Ban E-Cigarettes During COVID-19

    On April 1, 2020, the U.S. House of Representatives Subcommittee on Economic and Consumer Policy asked the U.S. Food and Drug Administration (FDA) to clear the market of e-cigarettes because of the COVID-19 coronavirus pandemic. It was responding to FDA’s request to give e-cigarette manufacturers four additional months to submit applications to stay on the market before enforcing a ban.  

    April 28, 2020
    FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer

    On March 27, 2020, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). 

    March 30, 2020
    Smoking Rates Are Low, But Here’s How They Can Be Lower
    Lung Cancer

    Smoking Rates Are Low, But Here’s How They Can Be Lower

    Although U.S. smoking rates have hit an all-time low of 14%, 34 million American adults are still considered active smokers, according to the U.S. surgeon general’s January 2020 report on smoking cessation. It’s the first new report focused directly on smoking cessation from the surgeon general’s office in 30 years. 

    March 04, 2020
    Cancer Death Rates See Largest-Ever Single-Year Drop
    American Cancer Society (ACS)

    Cancer Death Rates See Largest-Ever Single-Year Drop

    Overall U.S. cancer mortality fell 2.2% from 2016 to 2017, the largest reduction for a single year, according to the American Cancer Society’s “Cancer Statistics, 2020,” published in CA: A Cancer Journal for Clinicians.

    February 26, 2020
    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer
    Treatments

    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer

    Pegilodecakin, an investigational, first-in-class drug currently in clinical trials, is demonstrating positive safety results and measurable responses when used in combination with pembrolizumab or nivolumab in patients with non-small cell lung cancer (NSCLC) or kidney cancer. The findings from the multicenter, phase IB study were published in Lancet Oncology.

    January 28, 2020
    • Current page 1
    • Page 2
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲